US Court rules Ranbaxy's generic valganciclovir does not infringe Roche's Valcyte patent
Friday, October 16, 2009 08:00 IST Gireesh Babu, Mumbai
In a verdict on the patent litigation between Roche Palo Alto and the Daiichi-Ranbaxy on the former's patent rights with crystalline valganciclovir, the active ingredient in anti-viral drug Valcyte, the District Court of New Jersey
